Oruka Therapeutics, Inc. (ORKA) News
Track canonical SquawkNews coverage tagged to ORKA, Oruka Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing
() -- Arjun Agarwal, Senior Vice President, Finance, on July 13, 2026, sold 9,999 shares in Oruka Therapeutics (ORKA) for $846,180. Following the Form 4 filing with the SEC, Agarwal has control over a total of 15,312 com
GEOPOLITICS | Jul 13, 2026, 09:22 PM UTC
L
Oruka Therapeutics sharers are trading lower after a SEC filing disclosed that Fairmount Healthcare Fund II sold shares worth about $300 mil
Oruka Therapeutics sharers are trading lower after a SEC filing disclosed that Fairmount Healthcare Fund II sold shares worth about $300 million.
REGULATION | Jul 02, 2026, 03:42 PM UTC
L
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares
Oruka Therapeutics Inc. (NASDAQ: ORKA ) shares fell in after-hours trading on Wednesday after SEC filings showed major shareholder Fairmount Healthcare Fund II sold a large block of shares worth about $300 million. ORKA
REGULATION | Jul 02, 2026, 06:30 AM UTC
L
UBS Maintains Buy on Oruka Therapeutics, Raises Price Target to $130
UBS analyst Michael Yee maintains Oruka Therapeutics (NASDAQ: ORKA ) with a Buy and raises the price target from $100 to $130.
EQUITY | Jul 01, 2026, 04:13 PM UTC
M
ORKA: HC Wainwright Reiterates Buy
HC Wainwright & Co. reiterates buy rating on Oruka Therapeutics and maintains $120 price target
EQUITY | Jun 23, 2026, 10:52 AM UTC
H
DFTX +65% on Phase 3 Results
DFTX shares rise 65% on positive topline results from Phase 3 Emerge Study of DT120
EQUITY | Jun 22, 2026, 01:17 PM UTC
H
APGE +45% on Acquisition
AbbVie to acquire Apogee Therapeutics, sending APGE stock up 45% premarket
EQUITY | Jun 22, 2026, 12:21 PM UTC